JAMA · 1923 · 27 citations · 2 references
MedicineInfectious DiseasesPharmacotherapyImmunopharmacologyNeuroinfectious DiseasesNeuropharmacologyAnthelmintic PharmacologyAntiparasitic AgentsAntiparasitic TherapyNeurological Parasitic DiseasesTreatment Of TrypanosomiasisTrypanocidal Therapy
In the latter part of 1919, we entered on a study of the treatment of syphilis of the central nervous system with a view to the development and use of new drugs. At the suggestion of Dr. Wade H. Brown, we began our study with tryparsamid, the sodium salt of<i>N</i>-Phenyl-glycineamid-<i>p</i>-arsonic acid, C<sub>6</sub>H<sub>4</sub>(NHCH<sub>2</sub>CONH<sub>2</sub>) · (AsO · OH·ONa), which was first made by Jacobs and Heidelberger<sup>1</sup>in 1915. The biologic action of this substance has been studied experimentally by Brown and Pearce<sup>2</sup>in normal animals and in animals infected with trypanosomes and with the spirochetes of relapsing fever and of syphilis. Tryparsamid had also been used in a comparatively small group of patients for the treatment of syphilis other than that of the central nervous system, first by Louise Pearce and later by Keidel and Moore; and at the
2
STUDIES IN ASYMPTOMATIC NEUROSYPHILIS
Joseph E. Moore · Archives of internal medicine · 1922 · 26 citations · Full text